CYTO Stock: Altamira Therapeutics Ltd. Stock Price, Analysis & Insights
Get live CYTO stock price $0.30, comprehensive Altamira Therapeutics Ltd. stock analysis, charts, news, and expert forecast. Real-time CYTO stock data and investment insights.
Loading chart data...
Altamira Therapeutics Ltd. (CYTO) Overview
Altamira Therapeutics Ltd. (CYTO) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, CYTO trades at $0.30 with a market capitalization of 1.13M . Over the past 52 weeks, CYTO has traded between $0.30 and $0.42 , with the current price positioned at approximately 0% of this range . The stock currently trades ...
Key Takeaways
- Operates in the Healthcare sector (Biotechnology)
- Market cap: 1.13M
- Current price: $0.30
- 52-week range: $0.30 - $0.42
- P/E ratio: 0.16
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved. Its marketed offerings include Bentrio, a non-pharmaceutical nasal spray designed for individual prot...
Company Information
- CEO
- Thomas Meyer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
Contact Information
- Address
- Clarendon House
- Country
- BM
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 0.2)
✓ Higher growth potential with elevated volatility (Beta: 2.44)
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Altamira Therapeutics Ltd. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Altamira Therapeutics Ltd.
- ⚠Investors should consider how Altamira Therapeutics Ltd. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
1.13M
P/E Ratio (TTM)
0.16
Beta
2.44
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare CYTO with peer companies:
- Price
- $0.07
- Market cap
- 778.33K
- Price
- $0.41
- Market cap
- 1.19M
- Price
- $0.00
- Market cap
- 221
- Price
- $0.04
- Market cap
- 956.00K
- Price
- $0.00
- Market cap
- 9.08K
- Price
- $0.38
- Market cap
- 1.42M
- Price
- $0.00
- Market cap
- 145
- Price
- $0.32
- Market cap
- 995.92K
- Price
- $0.53
- Market cap
- 1.56M
- Price
- $0.34
- Market cap
- 1.18M
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.